IL155871A0 - Use of cci-779 as an antineoplastic agent - Google Patents
Use of cci-779 as an antineoplastic agentInfo
- Publication number
- IL155871A0 IL155871A0 IL15587101A IL15587101A IL155871A0 IL 155871 A0 IL155871 A0 IL 155871A0 IL 15587101 A IL15587101 A IL 15587101A IL 15587101 A IL15587101 A IL 15587101A IL 155871 A0 IL155871 A0 IL 155871A0
- Authority
- IL
- Israel
- Prior art keywords
- cci
- antineoplastic agent
- antineoplastic
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24907700P | 2000-11-15 | 2000-11-15 | |
PCT/US2001/047324 WO2002040000A2 (en) | 2000-11-15 | 2001-11-13 | Use of cci-779 as an antineoplastic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
IL155871A0 true IL155871A0 (en) | 2003-12-23 |
Family
ID=22941961
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15587101A IL155871A0 (en) | 2000-11-15 | 2001-11-13 | Use of cci-779 as an antineoplastic agent |
IL155871A IL155871A (en) | 2000-11-15 | 2003-05-12 | Use of 779-CCI for the preparation of a drug for the treatment of lupus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL155871A IL155871A (en) | 2000-11-15 | 2003-05-12 | Use of 779-CCI for the preparation of a drug for the treatment of lupus |
Country Status (28)
Country | Link |
---|---|
US (3) | US20020091137A1 (hu) |
EP (1) | EP1335725B1 (hu) |
JP (4) | JP4472251B2 (hu) |
KR (1) | KR100827942B1 (hu) |
CN (2) | CN1678312A (hu) |
AR (1) | AR031341A1 (hu) |
AT (1) | ATE393629T1 (hu) |
AU (2) | AU2731302A (hu) |
BR (1) | BR0115323A (hu) |
CA (1) | CA2429020C (hu) |
CY (1) | CY1108109T1 (hu) |
DE (1) | DE60133831T2 (hu) |
DK (1) | DK1335725T3 (hu) |
EA (1) | EA007096B1 (hu) |
ES (1) | ES2305134T3 (hu) |
HK (1) | HK1058008A1 (hu) |
HU (1) | HUP0400521A3 (hu) |
IL (2) | IL155871A0 (hu) |
MX (1) | MXPA03004192A (hu) |
NO (1) | NO20032181L (hu) |
NZ (1) | NZ539668A (hu) |
PL (1) | PL207061B1 (hu) |
PT (1) | PT1335725E (hu) |
SG (1) | SG148031A1 (hu) |
SI (1) | SI1335725T1 (hu) |
TW (1) | TWI286074B (hu) |
WO (1) | WO2002040000A2 (hu) |
ZA (1) | ZA200304603B (hu) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
CA2994779C (en) | 2001-02-19 | 2020-08-25 | Novartis Ag | Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
PL367267A1 (en) * | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
EA008379B1 (ru) * | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
JP2005531391A (ja) * | 2002-06-27 | 2005-10-20 | 微創医療器械(上海)有限公司 | 薬剤放出ステント |
PT1553940E (pt) | 2002-07-30 | 2008-05-09 | Wyeth Corp | Formulações parentéricas contendo um hidroxi-éster de rapamicina |
JP2006506353A (ja) * | 2002-09-17 | 2006-02-23 | ワイス | 経口処方 |
MXPA05005283A (es) | 2002-11-21 | 2005-07-25 | Wyeth Corp | Metodos para diagnostico de rcc y otros tumores solidos. |
US20050287532A9 (en) * | 2003-02-11 | 2005-12-29 | Burczynski Michael E | Methods for monitoring drug activities in vivo |
WO2004072265A2 (en) * | 2003-02-11 | 2004-08-26 | Wyeth | Methods for monitoring drug activities in vivo |
US7643943B2 (en) | 2003-02-11 | 2010-01-05 | Wyeth Llc | Methods for monitoring drug activities in vivo |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
TW200503753A (en) * | 2003-04-22 | 2005-02-01 | Wyeth Corp | Antineoplastic combinations |
AU2004235395A1 (en) * | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
KR20060052880A (ko) * | 2003-07-25 | 2006-05-19 | 와이어쓰 | 동결건조된 cci- 779 제형 |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
BRPI0418373A (pt) * | 2004-01-08 | 2007-05-22 | Wyeth Corp | composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
MX2007009812A (es) * | 2005-02-15 | 2007-10-23 | Wyeth Corp | Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles. |
TW200803892A (en) * | 2005-11-04 | 2008-01-16 | Wyeth Corp | Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272 |
EP1954269A2 (en) * | 2005-11-21 | 2008-08-13 | Novartis AG | Neuroendocrine tumor treatment using mtor inhibitors |
WO2007075621A1 (en) * | 2005-12-20 | 2007-07-05 | Wyeth | Control of cci-779 dosage form stability through control of drug substance impurities |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
CA2709413C (en) * | 2007-10-03 | 2017-09-12 | Genesis Technical Systems Corp. | Dynamic, asymmetric rings |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
PT2310011E (pt) | 2008-06-17 | 2013-10-07 | Wyeth Llc | Combinações antineoplásicas contendo hki-272 e vinorelbina |
KR20140069340A (ko) | 2008-08-04 | 2014-06-09 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
HUE061640T2 (hu) | 2009-04-06 | 2023-07-28 | Wyeth Llc | Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával |
WO2010132233A1 (en) * | 2009-05-13 | 2010-11-18 | The Trustees Of The University Of Pennsylvania | Combination antineoplastic therapy |
AU2011260016B2 (en) * | 2010-06-02 | 2013-08-22 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of Rapamycin esters |
US9745941B2 (en) * | 2014-04-29 | 2017-08-29 | Ford Global Technologies, Llc | Tunable starter resistor |
US10300026B2 (en) * | 2015-08-24 | 2019-05-28 | Shanxi Yabao Health Products Co., Ltd. | Use of dihydroxyacetone in preparation of anti-cancer medicaments |
CN111110676A (zh) * | 2020-03-07 | 2020-05-08 | 天津医科大学总医院 | 阿帕替尼及联合cci-779在制备肺癌药物中的应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
ES2084940T3 (es) | 1991-06-18 | 1996-05-16 | American Home Prod | Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. |
IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US6511986B2 (en) | 2000-08-11 | 2003-01-28 | Wyeth | Method of treating estrogen receptor positive carcinoma |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
TWI233359B (en) | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 CA CA002429020A patent/CA2429020C/en not_active Expired - Lifetime
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 EP EP01996175A patent/EP1335725B1/en not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/en active IP Right Grant
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko active IP Right Grant
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
-
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
-
2004
- 2004-02-10 HK HK04100881A patent/HK1058008A1/xx not_active IP Right Cessation
-
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
-
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
-
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
-
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
-
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2731302A (en) | Use of cci-779 as an antineoplastic agent | |
GB2359254B (en) | Formulation | |
AU8986501A (en) | Exemestane as chemopreventing agent | |
GB0000891D0 (en) | Formulation | |
EP1151667A3 (en) | Plant-activating agent | |
EP1163852A4 (en) | MASKING AGENT | |
GB2366727B (en) | Antithixotropic cosmetic agent | |
EP1291461A4 (en) | COLOR RECOVERY FUNDS | |
GB0019412D0 (en) | New imaging agent | |
AU2001275696A1 (en) | Therapeutic agent | |
AU5864901A (en) | 4-aminoquinolines as antiinfective agents | |
HK1053059A1 (zh) | 新用途 | |
GB0024517D0 (en) | Use of medicaments | |
GB0023220D0 (en) | Corticosteroid formulation | |
GB0009127D0 (en) | Vasodilatory agent | |
GB9921062D0 (en) | Use of cholestrol-lowering agent | |
GB0001144D0 (en) | Glysophosate formulation | |
GB0010846D0 (en) | Formulation | |
GB0023069D0 (en) | Formulation | |
GB0004124D0 (en) | Formulation | |
GB0007112D0 (en) | Formulation | |
PL340617A1 (en) | Derivatives of 2-acylpyridine | |
SI1301469T1 (sl) | Priprava 4-tioalkilbromobenzenskih derivatov | |
GB0109520D0 (en) | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors | |
GB0017049D0 (en) | Therapeutic agent |